PSMA is targeted via radioligand lutetium 177Lu vipivotide tetraxetan ([LuVT], Pluvicto, Novartis Pharmaceutical Corporation) to deliver beta-particle radiation to the PSMA-expressing tumor cells.1 The gene discussed is FOLH1; the disease is neoplasm.